Hoya Vision Care presents findings from the ARVO Annual Conference 2025
Hoya Vision Care announced at the ARVO (Association for Research in Vision and Ophthalmology) conference in June new clinical findings from three major clinical studies that underscore the impact of Defocus Incorporated Multiple Segments (D.I.M.S.) technology.
The results were presented as part of the company's scientific program, Exploring New Frontiers in Myopia Management with Miyosmart, at the ARVO Annual Meeting in Salt Lake City, Utah, USA.
The latest results from the world's longest running clinical trial of ophthalmic lenses for myopia management show that continuous wear of DIMS lenses significantly reduces myopia progression (-1.00 D ± 0.41 D, p=0.017) and axial elongation (0.42 ± 0.18 mm, p=0.019) over the entire follow-up period of 8 years (n=11).1 These findings show that continuous and long-term wear of Miyosmart lenses can improve the results of myopia management.
Dr. Natalia Vlasak, Global Head of Medical and Scientific Affairs at Hoya Vision Care, said: "This ground-breaking study, with the longest observation time ever for myopia treatment lenses, shows that long-term use of Miyosmart continues to significantly slow the progression of myopia, allowing children to enjoy their lives to the fullest. These results underscore the life-changing value of long-term fitting and provide important information and guidance for eye care professionals and parents who are committed to protecting children's vision in the future."
The first 12-month data from the randomized, controlled Aspect trial show that the combination of low-dose 0.025% atropine eye drops with DIMS lenses halted myopia progression in about 40 % of the children.2 The mean change in axial length, a key factor in myopia progression, was significantly lower than in the atropine-only group (0.07 ± 0.16 mm vs. 0.18 ± 0.16 mm; p<0.001). The researchers also examined vision-related quality of life (VR-QoL) and found a trend towards improvement in general vision (p=0.049) and competence (p=0.031) in children who received a combination of low-dose atropine and DIMS lenses.1
"Our results suggest that the combination of Miyosmart lenses with Atropine can achieve even better outcomes for children with progressive myopia - a positive step towards personalized, more powerful myopia treatment strategies that meet the individual needs of each child," said Dr. Natalia Vlasak, Global Head of Medical and Scientific Affairs at Hoya Vision Care.
A first-of-its-kind pilot study evaluating DIMS lenses for the treatment of myopia in 5- and 6-year-old children suggests that DIMS technology may have a protective effect against the development of myopia in this population. Over a nine-month period, the average cycloplegic spherical equivalent refraction (SER) remained stable with an annual change of +0.06 D compared to -0.15 D in a control group. While axial length increased slightly (22.48 mm to 22.64 mm, p<0.01), choroidal thickness remained stable. These promising initial results suggest that Miyosmart lenses can help prevent the development of myopia and delay the onset of myopia in pre-myopic preschool children, laying the foundation for future research.3
"With the alarming increase in myopia worldwide, the search for effective strategies to slow its progression has never been more urgent," said Dr. Vlasak. "With these studies, we continue to provide confidence to eye care professionals and parents with evidence of the benefits of Miyosmart lenses, both as monotherapy and in combination treatment. We are proud to fulfill our mission to protect every child's long-term vision and quality of life through our evidence-based innovations for the treatment of myopia."
References
1) Leung TW, et al. Comparison of Myopia Progression in Individuals Wearing Defocus Incorporated Multiple Segments (DIMS) Spectacle Lenses for Eight Years versus Shorter Durations. Poster number A0113. Presented 6th May, ARVO 2025.
2) Guemes-Villahoz N, et al. Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month results of a randomized controlled trial for myopia control using a combination of Defocus Incorporated Multiple Segments (DIMS) lenses and 0.025% atropine. Poster number B0466 . Presented 7th May, ARVO 2025.
3) Yang HY, Tsai DC. Efficacy of Defocus Incorporated Multiple Segments (DIMS) Lenses in Retarding Myopic Shifts Among Pre-Myopic Preschoolers: Nine-Month Results of a Pilot Study. Poster number A0104. Presented 7th May, ARVO 2025.
4) Garcia EH, et al. Vision-related quality of life in myopic children using combination treatment with atropine and DIMS (Defocus Incorporated Multiple Segments) spectacle lenses: 12-month results. Poster number A0297. Presented 5th May, ARVO 2025.
Source: www.hoya.ch
